US Stock MarketDetailed Quotes

BIOA BioAge Labs

Watchlist
  • 4.470
  • +0.150+3.47%
Close Mar 4 16:00 ET
160.24MMarket Cap-2.16P/E (TTM)

About BioAge Labs Company

BioAge Labs, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapeutic products for metabolic diseases, such as obesity, by targeting the biology of human beings. It offers Azelaprag, a potential oral therapeutic for obesity, followed by several earlier-stage metabolic programs. The company was founded by Kristen Fortney and Eric Morgen on April 1, 2015 and is headquartered in Richmond, CA.

Company Profile

SymbolBIOA
Company NameBioAge Labs
Listing DateSep 26, 2024
Issue Price18.00
Founded2015
CEODr. Kristen Fortney, PhD
MarketNASDAQ
Employees60
Fiscal Year Ends12-31
Address1445A South 50th Street
CityRichmond
ProvinceCalifornia
CountryUnited States of America
Zip Code94804
Phone1-510-806-1445

Company Executives

  • Name
  • Position
  • Salary
  • Dr. Kristen Fortney, PhD
  • Chief Executive Officer, President and Director
  • 1.38M
  • Dr. Eric Morgen, M.D.
  • Chief Operating Officer and Director
  • 872.80K
  • Dr. Dov A. Goldstein, M.B.A.,M.D.
  • Chief Financial Officer
  • --
  • Dr. Paul D. Rubin, M.D.
  • Chief Medical Officer
  • 840.83K
  • Dr. Jean-Pierre Garnier, PhD
  • Chairman of the Board
  • --
  • Patrick G. Enright, M.B.A.
  • Independent Director
  • --
  • Dr. Michael Harvey Davidson, M.D.
  • Independent Director
  • --
  • Dr. James I. Healy, M.D.,PhD
  • Independent Director
  • --
  • Rekha Hemrajani, M.B.A.
  • Independent Director
  • 40.00K
  • Dr. Vijay Pande, PhD
  • Independent Director
  • --

Trending Stocks

Reassessing Chinese Assets
Following the introduction of China's groundbreaking DeepSeek technology, Wall Street giants have revised their investment outlooks for the Chinese market.
Discussing
Big Tech’s earnings season in full swing! Nvidia is the only one left
On Thursday, $Amazon (AMZN.US)$ stock fell after the firm reported Q4 adjusted earnings of $1.86/share, vs estimates of $1.50/share, on reve Show More